Ublituximab in Multiple Sclerosis: New Insights from ECTRIMS 2025

As the 41st Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) opens its doors in Barcelona, Neuraxpharm Group is poised to make a strong showing in the relapsing multiple sclerosis (RMS) space. In partnership with TG Therapeutics, the company will present new clinical and real-world data on BRIUMVI® (ublituximab), underscoring its commitment to reshaping the MS treatment landscape through long-term efficacy, improved tolerability, and practical utility.

With BRIUMVI now approved in both the U.S. and Europe, the presentations at ECTRIMS 2025 aim to deepen clinician understanding of how the anti-CD20 monoclonal antibody is performing across both clinical trial settings and real-world practice. The featured data include a six-year follow-up of the pivotal ULTIMATE I and II trials, along with updates from two ongoing studies—ENHANCE and ENABLE—that examine modified dosing and real-world outcomes, respectively.

At the center of the program is an oral presentation by Dr. Bruce Cree of the UCSF Weill Institute for Neurosciences, who will deliver long-term results from the ULTIMATE I and II open-label extension studies. Scheduled for September 24, the session will highlight six years of cumulative data on BRIUMVI’s efficacy and safety in patients with relapsing forms of MS.

While earlier results from the ULTIMATE trials demonstrated significant reductions in annualized relapse rates and MRI disease activity compared to teriflunomide over 96 weeks, the extended data set offers a rare longitudinal lens into the therapy’s durability. Such insights are particularly valuable in MS, a disease characterized by chronic progression and the need for sustained disease control over decades.

In parallel, Neuraxpharm will present findings from the ENHANCE study in an ePoster session. Led by Dr. Barry Singer, the study evaluates the safety and tolerability of a modified dosing regimen of BRIUMVI. With the therapy already offering relatively short infusion times—just one hour every six months after the initial loading doses—ENHANCE may help inform further optimization for patient convenience without compromising safety.

Also available as an ePoster is the ENABLE study, the first Phase 4 observational research examining real-world outcomes in patients initiating BRIUMVI. Dr. Carrie Hersh of the Cleveland Clinic Lou Ruvo Center for Brain Health will present these data, which aim to capture how the therapy is being used across diverse clinical settings and patient profiles. Real-world evidence is playing an increasingly critical role in treatment evaluation, especially for newer therapies with limited long-term post-marketing data.

Neuraxpharm’s presence at ECTRIMS will also include a dedicated booth (#Stand04), where MS experts will lead Booth Talks to explore the evolving role of BRIUMVI in practice. These sessions are expected to blend interpretation of the new data with discussion on real-world integration, helping healthcare professionals navigate questions of patient selection, treatment sequencing, and monitoring.

As a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders, Neuraxpharm’s partnership with TG Therapeutics has brought fresh momentum to BRIUMVI’s launch and uptake across the continent. Their joint effort reflects a broader strategy to deliver high-value innovation in a therapeutic area where unmet needs persist, even amid growing competition in the anti-CD20 class.

With its expanding data footprint and practical advantages—including streamlined infusions and emerging real-world support—BRIUMVI is well-positioned to secure a growing share of the RMS market. The presentations at ECTRIMS 2025 reinforce this trajectory, offering new layers of evidence that speak not just to efficacy, but to the realities of MS care in both clinic and community.

For clinicians attending the congress—and for the broader MS community watching from afar—Neuraxpharm’s latest contributions may help clarify where BRIUMVI fits in the increasingly nuanced equation of MS treatment choice.